Nova Biomedical Corp.: FDA filings under this applicant name
FDA lists 129 510(k) clearances under 2 spellings of the applicant name “Nova Biomedical Corp.” (first 1977, latest 2026), across 32 product codes in 2 review panels. Median 510(k) review time under this name: 78 days. Since 2017 the median was 180 days, against 231 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 3 | 132 |
| 2013 | 2 | 200 |
| 2014 | 3 | 287 |
| 2015 | 4 | 88 |
| 2016 | 3 | 132 |
| 2017 | 4 | 156 |
| 2018 | 7 | 180 |
| 2019 | 2 | 58 |
| 2020 | 4 | 58 |
| 2021 | 0 | — |
| 2022 | 1 | 683 |
| 2023 | 1 | 456 |
| 2024 | 3 | 881 |
| 2025 | 0 | — |
| 2026 | 2 | 226 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Nova Biomedical Corp. took a median 180 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 231 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| CHL | Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph | 28 | 28 |
| JGS | Electrode, Ion Specific, Sodium | 21 | 21 |
| PZI | Prescription Use Blood Glucose Meter For Near-Patient Testing | 10 | 10 |
| JJY | Multi-Analyte Controls, All Kinds (Assayed) | 8 | 8 |
| CGA | Glucose Oxidase, Glucose | 7 | 7 |
| JFP | Electrode, Ion Specific, Calcium | 6 | 6 |
| NBW | System, Test, Blood Glucose, Over The Counter | 6 | 6 |
| CEM | Electrode, Ion Specific, Potassium | 4 | 4 |
| CGL | Electrode, Ion Based, Enzymatic, Creatinine | 3 | 3 |
| GKF | Instrument, Hematocrit, Automated | 3 | 3 |
Plus 22 more product codes.
Review panels
- Clinical Chemistry (118)
- Hematology (11)
Most recent Nova Biomedical Corp. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K251281 | Nova Max Creat eGFR Monitoring System | SHB | 2026-01-21 | 272 |
| K252206 | Nova Allegro UACR Assay, Nova Allegro Analyzer | CGX | 2026-01-09 | 179 |
| K221326 | Nova Allegro HbA1c Assay, Nova Allegro Analyzer | LCP | 2024-11-22 | 931 |
| K221813 | Nova Allegro UACR Assay, Nova Allegro Analyzer | CGX | 2024-11-19 | 881 |
| K232075 | StatStrip Glucose Hospital Meter System | PZI | 2024-02-23 | 226 |
| K221900 | Stat Profile Prime Plus Analyzer System | CHL | 2023-09-29 | 456 |
| K203549 | Nova Primary Glucose Analyzer System | CGA | 2022-10-18 | 683 |
| K200403 | Stat Profile Prime Plus Analyzer System | JGS | 2020-04-14 | 55 |
| K200204 | Stat Profile Prime Plus Analyzer System | GGZ | 2020-04-06 | 69 |
| K200349 | Stat Profile Prime Plus Analyzer System | CGA | 2020-03-13 | 30 |
119 earlier clearances. See the full list in Caduvo.
Recalls
41 product recalls in 15 recall events; 10 initiated in the last five years. Most recent: 2026-07-29.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Nova Biomedical Corp. is the lead sponsor of 1 device studies on ClinicalTrials.gov (0 active or recruiting). Most recent:
- NCT04035044: Study of the Analytical Performance of ALLEGRO™ Instrument (Completed, started 2017-06-01)
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Nova Biomedical Corp. (89)
- Nova Biomedical Corporation (40)
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Nova-Ventrx (12 510(k)s)
- Nova Medical Specialties (11 510(k)s)
- Nova Health Systems, Inc. (3 510(k)s)
- Nova Technology Corp. (3 510(k)s)
- Nova Corp. (1 510(k)s)
- Nova/Da Vinci Systems, Inc. (1 510(k)s)
- Nova Design Technologies, Ltd. (1 510(k)s)
- Nova Diversified Concepts (1 510(k)s)
- Nova Eye, Inc. (1 510(k)s)
- Nova Eye Inc. (Business Name Nova Eye Medical) (1 510(k)s)
- Nova Health Concepts, Inc. (1 510(k)s)
- Nova Implants , Ltd. (1 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Nova Biomedical Corp.?
FDA lists 129 510(k) clearances under 2 spellings of the applicant name “Nova Biomedical Corp.” (first 1977, latest 2026), across 32 product codes in 2 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Nova Biomedical Corp.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Nova Biomedical Corp. is 78 days. Since 2017: 180 days, versus 231 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Nova Biomedical Corp.?
The most frequent FDA product codes under this applicant name are CHL (Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph, 28); JGS (Electrode, Ion Specific, Sodium, 21); PZI (Prescription Use Blood Glucose Meter For Near-Patient Testing, 10).
Next steps
- See all 129 Nova Biomedical Corp. clearances with predicates and recalls
- Run predicate analysis for product code CHL, Nova Biomedical Corp.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.